Debiopharm, Aurigene ink Debio 1142 development pact
Debiopharm said Debio 1142 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumours, including resistance to chemotherapy. Aurigene CEO
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.